Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Liqing Jin, MD, Nathan Mbong, Stanley W.K. Ng, PhD, Jean C.Y. Wang, MD, Mark D. Minden, MD PhD, Jinhong Fan, Daniel W. Pierce, Michael Pourdehnad, MD, John E. Dick, PhD

Blood (2019) 134 (Supplement_1): 3940.

https://doi.org/10.1182/blood-2019-128450

Published: 2019

Journal Articles

Avadomide (CC-122) Alters T Cell Repertoire and Enhances Infiltration of Lymphocytes into Tumor Microenvironment in DLBCL Patients

Patrick R. Hagner, PhD, Fadi Towfic, PhD, Frank Schmitz, MD PhD, Xuehai Wang, PhD, Andrew P. Weng, MD, Michael Pourdehnad, MD, Anita K. Gandhi, PhD

Blood (2018) 132 (Supplement 1): 4211.

https://doi.org/10.1182/blood-2018-99-114481

Published: 2018

Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Umberto Vitolo, Marie José Kersten, MD PhD, Annalisa Chiappella, MD, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Rafael Sarmiento, Silvia Mosulen, PhD, Cristina Mendez, Shailaja Uttamsingh, PhD, Michael Pourdehnad, MD, Kristen Hege, MD, Li Li, Zariana Nikolova, MD PhD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 449.

https://doi.org/10.1182/blood-2018-99-110213

Published: 2018

Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2018) 132 (Supplement 1): 1602.

https://doi.org/10.1182/blood-2018-99-114409

Published: 2018

Journal Articles

CC-122, a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Umberto Vitolo, MD, Marie José Kersten, MD PhD, Annalisa Chiappella, MD, Pier Luigi Zinzani, MD, Rafael Sarmiento, Silvia Mosulen, PhD, Cristina Mendez, Michael Petrarca, PhD, Michael Pourdehnad, MD, Kristen Hege, MD, Li Li, Zariana Nikolova, MD PhD, Vincent Ribrag, MD

Blood (2017) 130 (Supplement 1): 411.

https://doi.org/10.1182/blood.V130.Suppl_1.411.411

Published: 2017

Journal Articles

A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC-122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B-Cell Lymphoma Subjects: Results from the Phase I CC-122-ST-001 Study

Blood (2017) 130 (Supplement 1): 4118.

https://doi.org/10.1182/blood.V130.Suppl_1.4118.4118

Published: 2017

Journal Articles

Discovery of an Immune-Driven Gene Expression Signature That Predicts for Clinical Benefit to CC-122 in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Alberto Risueño, PhD, Patrick R. Hagner, PhD, Celia Fontanillo, PhD, Amira Djebbari, DSc, Joel S. Parker, PhD, Clifton P. Drew, PhD, Fadi Towfic, PhD, Michael Pourdehnad, MD, Anita K. Gandhi, PhD, Matthew Trotter, PhD

Blood (2017) 130 (Supplement 1): 2830.

https://doi.org/10.1182/blood.V130.Suppl_1.2830.2830

Published: 2017

Journal Articles

CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2017) 130 (Supplement 1): 1551.

https://doi.org/10.1182/blood.V130.Suppl_1.1551.1551

Published: 2017

Journal Articles

CC-220 Is a Potent Cereblon Modulating Agent That Displays Anti-Proliferative, Pro-Apoptotic and Immunomodulatory Activity on Sensitive and Resistant Multiple Myeloma Cell Lines

Chad C Bjorklund, PhD, Jian Kang, Ling Lu, Michael Amatangelo, PhD, Hsiling Chiu, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Anke Klippel, PhD, Anjan Thakurta, PhD

Blood (2016) 128 (22): 1591.

https://doi.org/10.1182/blood.V128.22.1591.1591

Published: 2016

Journal Articles

CC-122 Is a Cereblon Modulating Agent That Is Active in Lenalidomide-Resistant and Lenalidomide/Dexamethasone-Double-Resistant Multiple Myeloma Pre-Clinical Models

Chad C Bjorklund, PhD, Jian Kang, Ling Lu, Michael Amatangelo, PhD, Hsiling Chiu, Patrick Hagner, PhD, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Anke Klippel, PhD, Anjan Thakurta, PhD

Blood (2016) 128 (22): 1592.

https://doi.org/10.1182/blood.V128.22.1592.1592

Published: 2016

Journal Articles

CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity

Hsiling Chiu, Patrick Hagner, PhD, Michael Pourdehnad, MD, Thomas Daniel, Rajesh Chopra, Anke Klippel, Christian Klein, PhD, Anjan Thakurta, Anita K. Gandhi, PhD

Blood (2015) 126 (23): 4007.

https://doi.org/10.1182/blood.V126.23.4007.4007

Published: 2015

Journal Articles

CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma

Blood (2015) 126 (23): 2704.

https://doi.org/10.1182/blood.V126.23.2704.2704

Published: 2015

Journal Articles

CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Cecilia Carpio, MD, Loïc Ysebaert, MDPhD, Raúl Cordoba, MD, Armando Santoro, MD, José Antonio López-Martín, MD, Juan Manuel Sancho, MD PhD, Carlos Panizo, PhD, Mecide Meric Gharibo, MD, Drew W Rasco, MD, Anne-Marie Stoppa, MD, Sylvia Damian, MD, Xin Wei, Patrick Hagner, PhD, Kristen Hege, Soraya Carrancio, PhD, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Vincent Ribrag, MD

Blood (2015) 126 (23): 1494.

https://doi.org/10.1182/blood.V126.23.1494.1494

Published: 2015

Journal Articles

CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse

Benedetta Apollonio, PhD, Mariam Fanous, BSc, MSc, Mohamed-Reda Benmebarek, BSc, MRes, Stephen Devereux, FRCP, FRCPath, PhD, Patrick Hagner, PhD, Michael Pourdehnad, MD, Anita K. Gandhi, PhD, Piers E. Patten, BSc, MRCP, MRCPath, PhD, Alan G. Ramsay, PhD

Blood (2015) 126 (23): 1738.

https://doi.org/10.1182/blood.V126.23.1738.1738

Published: 2015

Journal Articles

CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide

Jemma Blocksidge, Mark Glenn, Anita K. Gandhi, PhD, Anke Klippel, PhD, Michael Pourdehnad, MD, Rajesh Chopra, MD PhD, Nagesh Kalakonda

Blood (2014) 124 (21): 4682.

https://doi.org/10.1182/blood.V124.21.4682.4682

Published: 2014

Journal Articles

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

Patrick Hagner, PhD, Maria Wang, PhD, Suzana Couto, PhD, Mike Breider, DVM, PhD DACVP, Celia Fontanillo, PhD, Matthew Trotter, PhD, Chad C Bjorklund, PhD, Courtney G. Havens, PhD, Heather K Raymon, PhD, Rama Krishna Narla, PhD, Leo Barnes, PhD, Michelle Waldman, MS, Tom Daniel, MD, Anke Klippel, PhD, Michael Pourdehnad, MD, Anjan Thakurta, PhD, Rajesh Chopra, MD, PhD, Anita K. Gandhi, PhD

Blood (2014) 124 (21): 3035.

https://doi.org/10.1182/blood.V124.21.3035.3035

Published: 2014

Journal Articles

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

Vincent Ribrag, MD, Silvia Damien, MD, Mecide Gharibo, MD, Mercede Gironella, MD, Armando Santoro, MD, Drew W Rasco, MD, William Edenfield, MD, Xin Wei, PhD, Angela James, PhD, Patrick Hagner, PhD, Anita K. Gandhi, PhD, Rajesh Chopra, MD PhD, Jorge F. DiMartino, MD PhD, Michael Pourdehnad, MD, Anne-Marie Stoppa, MD

Blood (2014) 124 (21): 3500.

https://doi.org/10.1182/blood.V124.21.3500.3500

Published: 2014

NARROW

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Avadomide (CC-122) Alters T Cell Repertoire and Enhances Infiltration of Lymphocytes into Tumor Microenvironment in DLBCL Patients

Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

CC-122, a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC-122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B-Cell Lymphoma Subjects: Results from the Phase I CC-122-ST-001 Study

Discovery of an Immune-Driven Gene Expression Signature That Predicts for Clinical Benefit to CC-122 in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

CC-220 Is a Potent Cereblon Modulating Agent That Displays Anti-Proliferative, Pro-Apoptotic and Immunomodulatory Activity on Sensitive and Resistant Multiple Myeloma Cell Lines

CC-122 Is a Cereblon Modulating Agent That Is Active in Lenalidomide-Resistant and Lenalidomide/Dexamethasone-Double-Resistant Multiple Myeloma Pre-Clinical Models

CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity

CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma

CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma

CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse

CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only